Moderna has suffered its second PMCPA rebuke in quick succession. Days after ruling Moderna had brought discredit on the ...

After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

Otsuka is once again on the PMCPA’s naughty list as the U.K. drug marketing regulatory body has for the second time this year ...

AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

In the latest of several recent mpox vaccine supply deals, Bavarian Nordic plans to provide 1 million doses of its shot, ...

Vaccine maker CSL Seqirus has lined up yet another contract with the U.S. | With a $121.4 million award from the U.S.

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 ...

Spherix Global Insights has provided a different angle on AbbVie’s successful retention of Humira sales in the face of ...